MK-8507

Drug Merck Sharp & Dohme Corporation
Total Payments
$1.1M
Transactions
16
Doctors
0
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2020 $161,709 5 0
2018 $633,447 9 0
2017 $341,039 2 0

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $1.1M 16 100.0%

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
A Randomized Double-Blind Placebo-Controlled Trial to Assess the Pharmacokinetics of Urine and Plasma Fluoride Following Multiple Doses of MK-8507 Merck Sharp & Dohme Corporation $974,486 0
An Open-Label Trial to Assess the Two-Way Interaction Between Multiple, Once Weekly Oral Doses of MK-8507 and Single-Doses of Islatravir MK-8591 in Healthy Adults Merck Sharp & Dohme Corporation $161,165 0
A Trial to Assess the Effects of Multiple, Once Weekly Oral Doses of MK-8507 on the Single-Dose Pharmacokinetics of a Combination Oral Contraceptive Levonorgestrel and Ethinyl Estradiol in Healthy Adult Female Participants Merck Sharp & Dohme Corporation $544.60 0

Top Doctors Receiving Payments for MK-8507

Doctor Specialty Location Total Records
Unknown — Lincoln, NE $1.1M 16

Manufacturing Companies

Product Information

  • Type Drug
  • Total Payments $1.1M
  • Total Doctors 0
  • Transactions 16

About MK-8507

MK-8507 is a drug associated with $1.1M in payments to 0 healthcare providers, recorded across 16 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.

Payment data is available from 2017 to 2020. In 2020, $161,709 was paid across 5 transactions to 0 doctors.

The most common payment nature for MK-8507 is "Unspecified" ($1.1M, 100.0% of total).

MK-8507 is associated with 3 research studies, including "A Randomized Double-Blind Placebo-Controlled Trial to Assess the Pharmacokinetics of Urine and Plasma Fluoride Following Multiple Doses of MK-8507" ($974,486).